LY03017 vs Roluperidone
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Serotonin 5-HT2A receptor (antagonist / inverse agonist) · full Schizophrenia pipeline
LY03017
Developed by Luye Pharma Group
NCT06388551 · Phase 1 · status unknown
This early-phase study randomly assigned healthy volunteers to ascending single oral doses of LY03017 or matching placebo under quadruple-blind conditions, tracking adverse events as the primary outcome. No results have been posted, so it remains a well-designed, blinded, placebo-controlled trial whose findings are not yet known. Its registered primary outcome on ClinicalTrials.gov is "Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
No aligned efficacy figure on record for this race.
Roluperidone
Developed by Minerva Neurosciences
NCT03397134 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled Phase 3 efficacy trial with an adequate sample (513 patients) and a hard clinical primary endpoint: change in the validated PANSS Marder negative symptom factor score (NSFS) at 12 weeks. However, the primary endpoint comparison was not met under the protocol's predefined multiplicity-adjusted threshold (64 mg vs placebo p=0.043 exceeded the required p≤0.025), and the 32 mg dose showed essentially no separation from placebo. Because the primary result was non-significant, the trial provides real but limited evidence despite its strong design.
Next expected readout: December 2027 · NCT07565428 (registry estimate)
Reported efficacy
Change From Baseline to Week 12 in PANSS Marder Negative Symptoms Factor Score (NSFS) (Baseline, Week 2, Week 4, Week 8, and Week 12): Change From Baseline to Week 12 in PANSS Marder Negative Symptoms Factor Score (NSFS) (Baseline, Week 2, Week 4, Week 8, and Week 12): Roluperidone 32 mg — Baseline: 25.2 score on a scale (Standard Deviation 3.43); Change from Baseline to Week 2: -1.2 score on a scale (Standard Deviation 2.22); Change from Baseline to Week 4: -2.6 score on a scale (Standard Deviation 2.57); Change from Baseline to Week 8: -3.4 score on a scale (Standard Deviation 3.49); Change from Baseline to Week 12: -3.7 score on a scale (Standard Deviation 3.2) | Roluperidone 64 mg — Baseline: 25.3 score on a scale (Standard Deviation 3.26); Change from Baseline to Week 2: -1.7 score on a scale (Standard Deviation 2.47); Change from Baseline to Week 4: -2.8 score on a scale (Standard Deviation 2.92); Change from Baseline to Week 8: -3.8 score on a scale (Standard Deviation 3.32); Change from Baseline to Week 12: -4.5 score on a scale (Standard Deviation 3.85) vs Placebo — Baseline: 24.3 score on a scale (Standard Deviation 3.01); Change from Baseline to Week 2: -1.2 score on a scale (Standard Deviation 2.46); Change from Baseline to Week 4: -1.8 score on a scale (Standard Deviation 2.99); Change from Baseline to Week 8: -2.8 score on a scale (Standard Deviation 3.44); Change from Baseline to Week 12: -3.5 score on a scale (Standard Deviation 3.97) (missed)
Result source: NCT03397134
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | LY03017 | Roluperidone |
|---|---|---|
| PANSS total, change | —Not reported | —Trial running · NCT07565428 |
| CGI-S, change | —Not reported | -0.4 vs -0.3−0.1 vs placeboNCT033971347 other results
|
| PANSS response | —Not reported | —Trial running · NCT07565428 |
| PSP, change | —Not reported | 5 vs 3.1+1.9 vs placeboNCT033971343 other results
|
| Relapse (% of patients) | —Not reported | —Trial running · NCT07565428 |
PANSS total, change
- LY03017
- —Not reported
- Roluperidone
- —Trial running · NCT07565428
CGI-S, change
- LY03017
- —Not reported
- Roluperidone
- -0.4 vs -0.3−0.1 vs placeboNCT03397134
7 other results
- -0.4 vs -0.2 NCT03397134
- -0.3 vs -0.1 NCT03397134
- -0.1 vs -0.1 NCT03397134
- -0.4 vs -0.3 NCT03397134
- -0.3 vs -0.2 NCT03397134
- -0.2 vs -0.1 NCT03397134
- -0.1 vs -0.1 NCT03397134
PANSS response
- LY03017
- —Not reported
- Roluperidone
- —Trial running · NCT07565428
PSP, change
- LY03017
- —Not reported
- Roluperidone
- 5 vs 3.1+1.9 vs placeboNCT03397134
3 other results
- 3.2 vs 1.2 NCT03397134
- 3.6 vs 3.1 NCT03397134
- 1.6 vs 1.2 NCT03397134
Relapse (% of patients)
- LY03017
- —Not reported
- Roluperidone
- —Trial running · NCT07565428
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
LY03017: no structured comparison results are available for Schizophrenia.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Roluperidone
show 7 more results
show 3 more results
show 1 more result
show 7 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LY03017's landscape · Roluperidone's landscape